Multinational Pharmaceutical Firms' FDI in China

The opening-up of Chinese economy in 1978 and the
subsequent reforms provided multinational
corporations with tremendous opportunities to invest
in and explore the world's largest developing
market. China, however, presents a complicated and
difficult operating business environment for foreign
investors. This PhD thesis demonstrates a
comprehensive, multi-level study on 44 multinational
pharmaceutical firms' strategic planning and
implementation of foreign direct investment (FDI)
strategies in China during the first tweenty years
of China's open-door policy and economic reform era.
The study developed an integrated master conceptual
framework and examined a series of key issues
related to the strategic FDI decision-making and
implementation processes,
including FDI determinants, entry mode choice
between joint venture and wholly owned subsidiary,
joint venture partners selection, FDI operating
location choice within China, and the
determinants of FDI effectiveness and success in
China. The thesis received exemplary reports from
all examiners, and the PhD candidate was awarded
the Research Achievement Prize" by Swinburne
University.

Autorentext
Dr JIANG Fuming is a senior lecturer in the College of Business and Economics, Australian National University. He teaches international business and researches MNCs' FDI into and from China, and has published five books and sixteen articles in journals such as Journal of World Business, Journal of Business Strategies, Management Decision.